Suven Life shares close 7.5% up on securing molecule patent

Image
Press Trust of India Mumbai
Last Updated : Jul 13 2015 | 5:22 PM IST
Shares of Suven Life Sciences soared 7.5 per cent today after the company got patent from China, South Africa and Mexico for a molecule used in treating neuro-degenerative diseases.
The stock surged 7.09 per cent to settle at Rs 252.20 on the BSE. During the day, it jumped 8.66 per cent to Rs 255.90.
At the NSE, shares of the company rose by 7.46 per cent to Rs 252.60 at close.
In terms of volume, 4.94 lakh shares of the company changed hands at the BSE while over 23 lakh shares were traded at the NSE during the day.
Neuro-degenerative diseases include Alzheimer's, Schizophrenia and Parkinson's.
In a BSE filing, the company said it "secured patents from China and South Africa to the new chemical entities (NCE) for central nervous system (CNS) therapy".
Meanwhile, in the broader market, the benchmark BSE Sensex ended the day with a gain of 299.79 points at 27,961.19.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jul 13 2015 | 5:22 PM IST

Next Story